ProMetic Life Sciences’ (PLI) “Outperform” Rating Reaffirmed at Scotiabank
ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating restated by equities research analysts at Scotiabank in a research report issued to clients and investors on Thursday. They presently have a C$5.00 price objective on the stock. Scotiabank’s price objective would suggest a potential upside of 61.81% from the stock’s previous close.
A number of other research analysts have also weighed in on PLI. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of ProMetic Life Sciences in a research note on Thursday. CIBC decreased their price target on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. Finally, TD Securities reaffirmed a “speculative buy” rating and issued a C$4.50 price target on shares of ProMetic Life Sciences in a research note on Wednesday, September 28th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. ProMetic Life Sciences currently has a consensus rating of “Buy” and an average price target of C$4.84.
ProMetic Life Sciences (TSE:PLI) traded down 2.52% on Thursday, hitting $3.09. The stock had a trading volume of 1,302,903 shares. ProMetic Life Sciences has a 12 month low of $1.67 and a 12 month high of $3.62. The stock’s market cap is $1.87 billion. The firm’s 50 day moving average price is $2.92 and its 200-day moving average price is $3.01.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/prometic-life-sciences-inc-pli-given-a-c5-00-price-target-by-scotiabank-analysts.html
About ProMetic Life Sciences
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.